Login / Signup

Safety of fecal microbiota, live-jslm (REBYOTA ™ ) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials.

Christine LeeThomas LouieLindy BanckeBeth GuthmuellerAdam HarveyPaul FeuerstadtSahil KhannaRobert OrensteinErik R Dubberke
Published in: Therapeutic advances in gastroenterology (2023)
Across five clinical trials, RBL was well tolerated in adults with rCDI. In aggregate, these data consistently demonstrated the safety of RBL.
Keyphrases
  • clinical trial
  • electronic health record
  • big data
  • clostridium difficile
  • phase ii
  • machine learning
  • open label
  • double blind
  • study protocol